Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis

ABSTRACT

Objective: To characterize changes in myeloid and lymphoid innate immune cells in patients with relapsing-remitting multiple sclerosis (MS) during a 6-month follow-up after alemtuzumab treatment.

Methods: Circulating innate immune cells including myeloid cells and innate lymphoid cells (ILCs) were analyzed before and 6 and 12 months after onset of alemtuzumab treatment. Furthermore, a potential effect on granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-23 production by myeloid cells and natural killer (NK) cell cytolytic activity was determined.

Results: In comparison to CD4+ T lymphocytes, myeloid and lymphoid innate cell subsets of patients with MS expressed significantly lower amounts of CD52 on their cell surface. Six months after CD52 depletion, numbers of circulating plasmacytoid dendritic cells (DCs) and conventional DCs were reduced compared to baseline. GM-CSF and IL-23 production in DCs remained unchanged. Within the ILC compartment, the subset of CD56bright NK cells specifically expanded under alemtuzumab treatment, but their cytolytic activity did not change.

Conclusions: Our findings demonstrate that 6 months after alemtuzumab treatment, specific DC subsets are reduced, while CD56bright NK cells expanded in patients with MS. Thus, alemtuzumab specifically restricts the DC compartment and expands the CD56bright NK cell subset with potential immunoregulatory properties in MS. We suggest that remodeling of the innate immune compartment may promote long-term efficacy of alemtuzumab and preserve immunocompetence in patients with MS. 

Neurology.org/nn

2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
cells (ILCs). As orchestrators of immunity and tolerance induction, plasmacytoid DCs (pDCs) have been shown to modulate pathogenic T-cell responses, thus affecting autoimmune neuroinflammation.7–9 ILCs consist of 4 major subsets, including cytotoxic natural killer cells (NK cells) and 3 tissue-resident non-cytotoxic subsets, namely ILC1, ILC2, and group 3 ILC (ILC3 and lymphoid tissue inducer cells [LTi]).6 Frequencies of circulating LTis, and ILC subsets implicated in chronic inflammation, are increased in patients with multiple sclerosis (MS).10 Furthermore, NK-mediated control of T-cell activity11 has been shown to be impaired in MS,12,13 but can be restored by treatment with daclizumab.13

In this study, we investigated the phenotype and responses of innate immune cells in a 6-month follow-up study of alemtuzumab treatment to gain a better understanding of alemtuzumab-mediated effects on the innate immune response.

METHODS Patients and biomaterial. All patients were recruited at the Department of Neurology at the University Hospital Münster, Germany. Twelve patients with RRMS prior to and on alemtuzumab (Lemtrada) treatment (table 1, age 21–48 years, mean age 36.2 years, 6 female, 6 male) were included in the current study. Mean number of relapses was 2.4 ± 1.2 and mean Expanded Disability Status Scale (EDSS) progression was 1.2 ± 1.1 2 years prior to alemtuzumab initiation (table 1). Three patients were therapy-naïve and the other patients received pretreatments including azathioprine, β-interferons, glatiramer acetate, teriflunomide, fingolimod, natalizumab, mitoxantrone, and siponimod (within a clinical trial). So far none of the patients included in the study exhibited a secondary autoimmune disease. PBMCs were isolated from ethylenediaminetetraacetic acid blood derived from these patients at baseline (n = 12) and 6 (n = 12) and 12 months (n = 8) after standard treatment regimen of alemtuzumab (table 1) and cryopreserved as previously described.14

Table 1 Patient demographics

<table>
<thead>
<tr>
<th>No.</th>
<th>Age, y</th>
<th>Sex</th>
<th>Relapses 2 years prior to treatment</th>
<th>EDSS, 2 y</th>
<th>EDSS, 0 mo</th>
<th>EDSS, 6 mo</th>
<th>PBMC/mL, 0 mo (×10⁶)</th>
<th>PBMC/mL, 6 mo (×10⁶)</th>
<th>SAD</th>
</tr>
</thead>
<tbody>
<tr>
<td>1²</td>
<td>44</td>
<td>F</td>
<td>3</td>
<td>1.0</td>
<td>4.0</td>
<td>4.0</td>
<td>2.83</td>
<td>1.33</td>
<td>None</td>
</tr>
<tr>
<td>2²</td>
<td>26</td>
<td>F</td>
<td>4</td>
<td>1.0</td>
<td>4.0</td>
<td>4.0</td>
<td>1.12</td>
<td>0.65</td>
<td>None</td>
</tr>
<tr>
<td>3²</td>
<td>45</td>
<td>F</td>
<td>1</td>
<td>0.0</td>
<td>4.5</td>
<td>4.5</td>
<td>2.48</td>
<td>1.10</td>
<td>None</td>
</tr>
<tr>
<td>4²</td>
<td>38</td>
<td>M</td>
<td>3</td>
<td>2.5</td>
<td>2.5</td>
<td>2.5</td>
<td>5.17</td>
<td>1.09</td>
<td>None</td>
</tr>
<tr>
<td>5²</td>
<td>43</td>
<td>F</td>
<td>2</td>
<td>1.0</td>
<td>4.0</td>
<td>4.0</td>
<td>2.26</td>
<td>1.20</td>
<td>None</td>
</tr>
<tr>
<td>6²</td>
<td>21</td>
<td>M</td>
<td>5</td>
<td>0.0</td>
<td>1.5</td>
<td>1.5</td>
<td>1.26</td>
<td>0.83</td>
<td>None</td>
</tr>
<tr>
<td>7²</td>
<td>24</td>
<td>M</td>
<td>1</td>
<td>0.5</td>
<td>2.5</td>
<td>2.5</td>
<td>1.25</td>
<td>1.48</td>
<td>None</td>
</tr>
<tr>
<td>8²</td>
<td>27</td>
<td>M</td>
<td>2</td>
<td>1.0</td>
<td>2.0</td>
<td>2.0</td>
<td>1.84</td>
<td>1.14</td>
<td>None</td>
</tr>
<tr>
<td>9²</td>
<td>42</td>
<td>M</td>
<td>1</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>1.18</td>
<td>1.05</td>
<td>None</td>
</tr>
<tr>
<td>10</td>
<td>48</td>
<td>F</td>
<td>3</td>
<td>3.5</td>
<td>6.5</td>
<td>6.5</td>
<td>1.33</td>
<td>0.70</td>
<td>None</td>
</tr>
<tr>
<td>11</td>
<td>34</td>
<td>F</td>
<td>2</td>
<td>1.5</td>
<td>4.5</td>
<td>3.5</td>
<td>2.92</td>
<td>0.83</td>
<td>None</td>
</tr>
<tr>
<td>12</td>
<td>42</td>
<td>M</td>
<td>2</td>
<td>2.0</td>
<td>2.0</td>
<td>2.0</td>
<td>2.92</td>
<td>0.83</td>
<td>None</td>
</tr>
</tbody>
</table>

Abbreviations: EDSS = Expanded Disability Status Scale; PBMC = peripheral blood mononuclear cell; SAD = secondary autoimmune disease.
²Patient included in figure e-1.

Standard protocol approvals, registrations, and patient consents. This study was performed according to the Declaration of Helsinki and approved by the local ethics committee (2014-398-F-S). All patients gave written informed consent.

Stimulation of DCs. For the identification of cytokine production in myeloid cells, freshly thawed PBMCs were stimulated with 200 ng/mL lipopolysaccharide (Sigma-Aldrich, St. Louis, MO) in X-Vivo 15 (Lonza Group, Basel, Switzerland) supplemented with Brefeldin A (5 µg/mL) and Monensin (2 µM) (BioLegend, San Diego, CA) at a concentration of 1 × 10⁶ cells/mL for 10 hours at 37°C, 5% CO₂. Subsequently, cells were stained for flow cytometry as described below.

Flow cytometry. Flow cytometry of thawed PBMCs was performed as previously described14 using the respective fluorochrome-conjugated antibodies at the indicated working concentrations (table e-1 at Neurology.org/nn). Staining for chemokine receptors was done at 37°C. Intracellular staining for cytokines was performed using the intracellular staining kit (eBioscience, San Diego, CA) following the manufacturer’s instructions. Samples were acquired on a 10-color Navios (Beckman Coulter, Sharon Hill, PA) or FACSCanto II (BD Biosciences, East Rutherford, NJ) flow cytometer and analyzed by FlowJo v10 and Kaluza 1.3. The gating strategies to determine innate myeloid and lymphoid subsets were described in the respective figures. T-regulatory cells were phenotypically characterized by FoxP3 expression among gated CD3⁺ CD4⁺ T cells.

NK-cell degranulation assay. Degranulation of interleukin (IL)-15-activated NK cells in response to K562, 721.221, and allogeneic CD4⁺ T cells was determined as previously described.13,15 Staphylococcal enterotoxin B (SEB; Sigma-Aldrich)–activated CD4⁺
T cells were generated by stimulation of thawed PBMCs in RPMI 1640 medium supplemented with 10% heat-inactivated FCS, 200 IU/mL recombinant human IL-2 (eBioscience), and 100 μg/mL SEB at cell densities of 2 × 10⁶ cells/mL for 4 days at 37°C. CD4⁺ T cells were isolated using the CD4⁺ T cell Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer’s instructions.

**Statistical analysis.** Data were analyzed using GraphPad Prism v5.04 (La Jolla, CA). Depending on the outcome of D’Agostino and Pearson omnibus normality test, groups of 2 datasets were compared by paired or unpaired Student t test and Wilcoxon matched-pairs signed rank test or Mann-Whitney test, respectively. Datasets of 3 or more groups were analyzed by 1-way analysis of variance (ANOVA) or repeated-measures ANOVA with Bonferroni posttest or for non-Gauss distributed data Kruskal-Wallis test or Friedman test with Dunn post-test, respectively. Datasets with too few data points to perform testing for Gaussian distribution were analyzed as Gaussian distributed. Results were regarded as statistically significant with the following p values: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

**RESULTS** In accordance with previous studies, proportions and numbers of CD4⁺ T cells markedly declined 6 months after alemtuzumab treatment (figure e-1A). In comparison to CD4⁺ T cells, DCs (figure 1A), monocytes (figure 1B), and ILCs (figure 1C) derived from patients with RRMS expressed significantly lower amounts of CD52 on their cell surface. Interestingly, despite low cell surface expression of CD52, alemtuzumab treatment altered proportions of pDCs (figure e-1B), monocytes (figure e-1C), and ILCs (figure e-1D), with most of the changes occurring 6 months after treatment onset. Thus, the effect of alemtuzumab treatment on these innate myeloid and lymphoid cell subsets as well as their phenotype and function were further investigated using PBMCs derived from 12 patients with RRMS (table 1) before and 6 months after treatment onset. Patients with RRMS remained clinically stable during the 6-month follow-up (table 1, EDSS 3.2 ± 1.7 at baseline vs 3.0 ± 1.8 at 6 months) and none of the investigated patients experienced any further relapse. In accordance with the alemtuzumab-induced lymphopenia, total numbers of PBMCs were strongly reduced in patients with RRMS following 6 months of alemtuzumab treatment (table 1, 2.22 ± 1.17 × 10⁶ PBMC/mL at baseline vs 1.02 ± 0.26 × 10⁶ PBMC/mL at 6 months).

Within the innate myeloid cell compartment (figure 2A), decreased numbers of circulating conventional CD14⁺CD16⁻ DCs and CD1c⁺ DCs as well as pDCs were observed in alemtuzumab-treated patients (figures 2B and e-2A), resulting in a relative increase of monocytes after 6 months (figures 3, A and B, and e-2B).

While lower numbers of circulating DC subsets were observed in alemtuzumab-treated patients, IL-23 and granulocyte-macrophage colony-stimulating factor (GM-CSF) production by DCs remained unaltered in patients with MS and healthy donors (figure 4A and data not shown). GM-CSF production by monocytes also remained unaltered (figure 4, B and C), whereas proportions of IL-23-producing monocytes (figure 4B) including the CD14⁺CD16⁻ classical monocyte subset (figure 4C and data not shown) were mildly enhanced in alemtuzumab-treated patients and healthy donors compared to baseline.

**Figure 1** CD52 expression on innate myeloid and lymphoid cell subsets

A. Dendritic cells

- CD4
- CD4⁺
- CD1c⁺
- pDC

B. Monocytes

- CD4
- CD14⁺CD16⁻
- CD14⁺CD16⁺

C. Innate lymphocytes

- CD4
- ILC
- CD56<sup>bright</sup>
- CD56<sup>dim</sup>
- LTi

Peripheral blood mononuclear cells derived from treatment-naive patients with relapsing-remitting multiple sclerosis (n = 5, down triangles) were stained with fluorochrome-conjugated antibodies specific for (A) dendritic cell subsets, (B) monocyte subsets, and (C) innate lymphoid cell subsets as well as for CD52. CD52 expression on CD4⁺ T cells served as a positive control. Left: histograms of one representative donor show CD52 expression of the respective cell subset (dark gray) in comparison to the isotype control (light gray). Right: graphs display the median fluorescence intensities (MFI) of the respective cell subsets. Error bars indicate the SD. p Values were calculated by unpaired Student t test, ***p < 0.001, ****p < 0.0001. ILC = innate lymphoid cell; LTi = lymphoid tissue inducer cell.

© 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
With regard to CD4$^+$ T-cell subsets, a relative increase of proinflammatory T-helper (Th) 17 as well as immune-regulatory CD4$^+$ T cells within the CD4$^+$ subset was observed, while proportions within PBMCs and total numbers of these subsets were decreased 6 months after alemtuzumab treatment (figure e-3, *).
Interestingly, alemtuzumab-induced decrease of circulating CD4\(^+\) Th cells was accompanied by significantly increased proportions of ILC subsets (figure 5, A and B), the innate counterparts of the respective Th cell subset. Within the ILC compartment, reduced proportions and numbers of proinflammatory LTi were observed, whereas frequencies and numbers of immune-regulatory CD56\(^{bright}\)NK cells were significantly increased (figure 5B). In accordance with the relative increase of ILCs, CD56\(^{dim}\) NK cells the major ILC subset, were also enhanced within the PBMCs (figure e-4). However, this increase was relative, because proportions

(A) Gating strategy for monocytes. Monocytes and their subsets were separated from the total lineage (CD3, CD19) negative compartment based on the expression of CD14, CD16, and human leukocyte antigen-DR (HLA-DR), as previously described.\(^3^2\) (B) Graphs display proportions of monocytes within peripheral blood mononuclear cells or the respective subsets within monocytes (upper row) and total cell numbers (lower row) of monocyte subsets derived from alemtuzumab-treated patients with relapsing-remitting multiple sclerosis (n = 12) at baseline (filled triangles) and 6-month follow-up (open triangles). \(p\) Values were calculated by paired Student t test or Wilcoxon matched-pairs signed rank test, respectively, *\(p\ < 0.05, **\(p\ < 0.01, ***p\ < 0.001.\)
of CD56dim NK cells within the ILC subpopulation as well as their cell numbers remained unaltered (figure 5B). Finally, cytolytic activity of NK cells toward major histocompatibility complex–I-deficient target cell lines as well as antigen-activated CD4+ T cells was sustained in patients treated with alemtuzumab (figure 5C).

**DISCUSSION**

We investigated phenotype and effector function of innate immune cells in patients with RRMS in a 6-month follow-up study after a first cycle of alemtuzumab treatment. We found that alemtuzumab reduced numbers of specific DC subsets capable of eliciting detrimental immune responses in MS, but did not affect their IL-23 and GM-CSF production. Alemtuzumab-induced decrease of CD4+ T cells was accompanied by an increase in ILC frequencies, mainly caused by expansion of the CD56bright NK cells subset known to harbor potent immunoregulatory properties.11,13,16 However, the cytolytic function of NK cells was not altered 6 months after alemtuzumab treatment. These data indicate that alemtuzumab treatment in patients with RRMS restricts DC responses, while NK-cell activity is preserved. We suggest that these immunomodulatory properties of alemtuzumab might contribute to its long-term beneficial effects and preserved immunocompetence in patients with RRMS.

Despite their low surface expression of CD52, DCs were effectively depleted by alemtuzumab treatment,17,18 and rapid reconstitution of DCs has been observed in recipients of allogeneic stem cell transplantation with prior immune conditioning.19,20 Thus, it was an unexpected finding of our study that numbers of peripheral DCs including conventional DCs as well as pDCs were reduced 6 months after alemtuzumab treatment. Both DC subsets have been shown to exhibit specialized functions pivotal in the pathogenesis of MS.21,22 Conventional DCs induce Th1- and Th2-associated cytokines in RRMS and are cellular producers of IL-23.23,24 pDCs instead display a limited capacity to induce T-cell responses under steady-state conditions, but undergo functional specialization in MS with the capacity to prime IL-17-secreting T cells.25 Our results suggest that alemtuzumab targeting of pDCs might provide an additional beneficial mechanism in RRMS by downregulating detrimental adaptive immune responses.

Alemtuzumab did not affect surface expression levels and activation-dependent upregulation of the costimulatory molecules CD40 and CD80 on DCs in a low number of patients analyzed. In addition, human leukocyte antigen–DR expression was equally inducible after 6 months in CD1c+ DCs as compared to stimulated cells from untreated patients (figure e-5A). Additional pilot data from this study point to an equivalent production of tumor necrosis factor, IL-6, and IL-12 by myeloid cells 6 months after alemtuzumab treatment (figure e-5, B and C). We showed before that specifically IL-23 production by DCs is essential for the maintenance of Th17 lymphocytes and has previously been suggested as a therapeutic target in MS.9,26 Alemtuzumab did not alter GM-CSF and IL-23 production in DCs.

**Figure 4** Alemtuzumab-mediated effects on interleukin (IL)–23 and granulocyte-macrophage colony-stimulating factor (GM-CSF) production in innate myeloid cells

**Graphs** display proportions of IL-23 and GM-CSF producing (A) CD11c+ dendritic cells (DCs), (B) monocytes, and (C) CD14+CD16+ classical monocytes derived from alemtuzumab-treated patients with relapsing-remitting multiple sclerosis (n = 12) at baseline (filled triangles) and 6-month follow-up. p Values were calculated by paired Student t test or Wilcoxon matched-pairs signed rank test, respectively, *p < 0.05.
Figure 5  Alemtuzumab-induced changes in the innate lymphoid cell (ILC) compartment

(A) Gating strategy for ILCs. ILCs were defined as lineage (CD3, CD14, CD19, CD20)-negative peripheral blood mononuclear cells (PBMCs) devoid for dendritic cell (DC) markers CD123 and CD11c. CD56<sup>bright</sup>CD16<sup>dim</sup>CD16<sup>−</sup>NK cells were gated from CD56<sup>−</sup>NKp46<sup>−</sup> ILC, whereas CD117<sup>+</sup>CRTH2<sup>−</sup> lymphoid tissue inducer cells (LTis) were gated from CD56<sup>−</sup>NKp46<sup>−</sup> ILCs. (B) Graphs display proportions of ILCs within PBMCs or ILC subsets within ILCs (upper row) and total cell numbers (lower row) of ILC subsets derived from alemtuzumab-treated patients with relapsing-remitting multiple sclerosis (n = 12) at baseline (filled triangles) and 6-month follow-up (open triangles). (C) Release of cytolytic granules by NK cells at baseline and 6 months after alemtuzumab therapy (n = 7) in response to K562 (left), 721.221 (middle), or antigen-activated allogenic CD4<sup>+</sup> T cells. p Values were calculated by paired Student t test or Wilcoxon matched-pairs signed rank test, respectively, *p < 0.05, **p < 0.01, ***p < 0.001.
and mildly increased IL-23-producing monocytes 6 months after treatment. Additional study data from 8 treated patients pointed towards a reduction of IL-23-producing monocyte counts to baseline levels after 12 months (figure e-5D). The relevance of transient enhanced IL-23 production in this monocyte subset in alemtuzumab patients is unclear but may point towards compensatory effects.

NK cells have been suggested as additional players of the innate compartment in regulating T-cell responses in MS.\textsuperscript{11,13,27} Beneficial effects of daclizumab, a humanized monoclonal antibody directed against the IL-2 receptor chain,\textsuperscript{28} are associated with increased numbers and function of the CD56\textsuperscript{bright} NK-cell subset in patients with RRMS.\textsuperscript{11,13} Strikingly, our data revealed that alemtuzumab treatment also expanded this immune-regulatory NK-cell subset, emphasizing a potential role for the CD56\textsuperscript{bright} NK-cell subset in alemtuzumab-treated patients with RRMS. However, in contrast to daclizumab, alemtuzumab did not change the cytolytic activity of NK cells in response to antigen-activated CD4\textsuperscript{T} T cells. Of note, increased numbers of CD56\textsuperscript{bright} NK cells have also been observed in several autoimmune settings such as Hashimoto thyroiditis.\textsuperscript{29} Secondary autoimmune diseases including Hashimoto thyroiditis are common adverse reactions following alemtuzumab therapy.\textsuperscript{30,31} Although the underlying mechanisms of autoimmunity following alemtuzumab therapy have not yet been resolved, one can speculate on the functional implication of CD56\textsuperscript{bright} NK cells in this process.

Altogether, this study elucidates the repopulation dynamics and immune responses of innate immune cells in alemtuzumab-treated patients with RRMS. A limitation of our approach is the low number of patients included and the lack of functional assays addressing antigen uptake, processing, and presentation capacities of DCs that preclude final conclusions from our study.

Future controlled studies may expand our observations by addressing the role of innate immunity in alemtuzumab-treated patients with RRMS. Additional studies are required to understand the effect of alemtuzumab on the innate immune system in patients with RRMS. Our study suggests that alemtuzumab exerts disease-modulating activity by reducing DC numbers and preserving NK-cell responses in RRMS. Thus, remodeling of the innate immune compartment might add a beneficial treatment effect by alemtuzumab in RRMS.

**AUTHOR CONTRIBUTIONS**

J.A. and C.C.G. conceptualized the study, designed research, analyzed and interpreted the data, and wrote the manuscript. D.A. and A.S.M. performed research, collected and analyzed data, and helped with writing the manuscript. S.G.M. and T.R. organized patient recruitment, took care of patients, provided clinical information, and critically edited the manuscript. K.S. performed research and collected data. S.S. designed research and critically edited the manuscript. L.K., N.M., S.W., and B.G. were responsible for patient care, provided clinical information, and critically edited the manuscript. H.W., V.A., and S.J. helped to conceptualize the project and critically edited the manuscript.

**ACKNOWLEDGMENT**

The authors thank Daniela Roosterman, Verena Schütte, Kerstin Gotschalk, Schumina Sauberlich, Karla Musiolik, and Sarah Spielmann for technical assistance and all participants who donated blood in order to realize this study.

**STUDY FUNDING**

This study was supported by the Krankheitsbezogene Kompetenzzentren Multiple Sklerose (Disease-Related Competence Network for Multiple Sclerosis) funded by the Federal Ministry of Education and Research (FKZ 01FI1603A to H.W., L.K., and C.C.G.; 01GI0907B1 to H.W.; 01GI1603D to S.G.M., T.R., and H.W.) and the Collaborative Research Centre CRC TR128 “Initiating/effector vs regulatory mechanisms in multiple sclerosis: progress towards tackling the disease” (Projects A9 to H.W. and C.C.G. and Z2 to H.W.). The work of C.C.G. has been funded by the individual research grant “The role of natural killer cells in the immunoregulation of multiple sclerosis” by the German Research Foundation (DFG, GR3946/2-1). Also supported by DFG EXC 1003, Grant FF-2014-01, Cells in Motion–Cluster of Excellence, München, Germany, to J.A.; DFG SCHE692/3-1 to S.S.; and Strategic Research Fund of the Heinrich Heine University Düsseldorf (SFF-F2012/79-5-Scheu) to S.S. This study has also been supported by Genzyme Therapeutics Ltd., United Kingdom (“Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential” [ALAIN] to H.W., S.G.M., and T.R.).

**DISCLOSURE**

J.A., D.A., A.S.M., K.S., S.J., S.S., and B.G. have no financial disclosures. C.C.G. received speaker honoraria and travel expenses for attending meetings from Genzyme, Novartis Pharma GmbH, and Bayer Health Care. T.R. received travel expenses and financial research support from Genzyme and Novartis and has received honoraria for lecturing from Genzyme, Biogen, and Teva. S.W. received speaker honoraria from Bayer Vital, Biogen, Merck Serono, Novartis Pharma, and TEVA Pharma. N.M. received honoraria for lecturing and travel expenses for attending meetings from Biogen Idec, GlaxoSmithKline, Teva, Novartis Pharma, Bayer Healthcare, and Fresenius Medical Care and received financial research support from Fresenius Medical Care. L.K. received compensation for serving on Scientific Advisory Boards for Genzyme. She received speaker honoraria and travel support from Novartis, Merck Serono, and CSL Behring. She receives research support from Novartis. V.A. is a member of advisory boards and/or gave presentations for the following companies: Astra-Zeneca, Eli Lilly, Jansen-Organon, Lundbeck, Otsuka, Servier, and Trommsdorff. H.W. received compensation for serving on Scientific Advisory Boards/Steering Committees for Bayer Healthcare, Biogen, Genzyme, Merck Serono, Novartis, and Sanofi Aventis. He also received speaker honoraria and travel support from Bayer Vital GmbH, Bayer Schering AG, Biogen, CSL Behring, Fresenius Medical Care, Genzyme, Glaxo Smith Kline, GW Pharmaceuticals, Lundbeck, Merck Serono, Otsiamed, Novartis, and Sanofi-Aventis. He received compensation as a consultant from Biogen, Merck Serono, Novartis, and Sanofi-Aventis. H.W. received research support from Bayer Vital, Biogen, Genzyme, Merck Serono, Novartis, Sanofi Aventis Germany, and Sanofi US. S.G.M. has received honoraria for lecturing and travel expenses for attending meetings and has received financial research support from Bayer, Bayer Schering, Biogen Idec, Genzyme, Merck Serono, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi-Aventis, and Teva. Go to Neurology.org/nn for full disclosure forms.

Received May 4, 2016. Accepted in final form August 12, 2016.

**REFERENCES**


Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis
Catharina C. Gross, Diana Ahmetspahic, Tobias Ruck, et al.
Neurol Neuroimmunol Neuroinflamm 2016;3;
DOI 10.1212/NXI.0000000000000289

This information is current as of October 12, 2016